This study is testing a new therapeutic cancer vaccine, AST-201, for people with newly diagnosed advanced ovarian cancer (Stage III) that has a specific genetic feature called Homologous Recombination Proficiency (HRP). You would have already had surgery to remove as much of the cancer as possible. The study wants to see if adding AST-201, along with rhuGM-CSF (a protein that stimulates white blood cells), to standard chemotherapy (Paclitaxel and Carboplatin) can help you live longer without the cancer growing or coming back. Some participants will receive AST-201 and rhuGM-CSF, while others will receive a placebo (an inactive substance) and rhuGM-CSF, all in combination with standard chemotherapy. The study aims to enroll 98 participants.

Study design

This interventional study is comparing two groups of participants to see if adding AST-201 to standard chemotherapy improves outcomes. It plans to enroll 98 participants.

What's involved

You would undergo a screening period of up to 28 days, followed by approximately 5 months of treatment. The vaccine and rhuGM-CSF (or placebo) are given as injections under the skin every 3 weeks for 3 cycles, while chemotherapy is given every 3 weeks for 6 cycles.

Compensation

Not stated in the trial record.

Follow-up

After treatment, you will have follow-up visits every 3 months for 2 years, then every 6 months until your disease progresses, you pass away, or you withdraw consent. The overall study duration is approximately 48 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.